MétaCan
Menu
Back to cohort
Record W4411884110 · doi:10.3899/jrheum.2025-0314.82

Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2B/3 Trials

2025· article· en· W4411884110 on OpenAlexaffvenue
Nigil Haroon, Irene van der Horst-Bruinsma, Matthew Brown, F. van Gaalen, Lianne S. Gensler, Alexander Marten, George Stojan, T. Vaux, Katy White, Atul Deodhar, Martín Rudwaleit

Bibliographic record

VenueThe Journal of Rheumatology · 2025
Typearticle
Languageen
FieldMedicine
TopicOcular Diseases and Behçet’s Syndrome
Canadian institutionsUniversity Health Network
Fundersnot available
KeywordsMedicineMedDRAUveitisPsoriatic arthritisIncidence (geometry)Internal medicinePsoriasisSpondylarthropathiesSpondyloarthropathyAxial spondyloarthritisAnterior uveitisHLA-B27ArthritisDermatologyGastroenterologyImmunologyAdverse effectAntigenSacroiliitisHuman leukocyte antigenPharmacovigilance

Abstract

fetched live from OpenAlex

Objectives Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL17A. Here, we report long-term incidence of acute anterior uveitis (uveitis’) following BKZ treatment in patients (pts) with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). Methods Safety data are reported for 2 pools, each comprising 3 phase 2b/3 studies and their open-label extensions, in pts with active axSpA (non-radiographic and radiographic axSpA) and active PsA, respectively. Uveitis events were identified using the preferred terms “autoimmune uveitis,” “iridocyclitis,” “iritis,” and “uveitis,” coded according to MedDRA v19.0; note that “acute anterior uveitis” was not a specific preferred term available in MedDRA v19.0. Uveitis rates and exposure-adjusted incidence rates (EAIR) per 100 pt-years (PY) for pts who received ≥1 BKZ 160 mg dose are reported (data cutoff: July 2023). Results Pts with axSpA (N=848) had a mean age (standard deviation [SD]) of 40.3 (11.9) years, and pts with PsA (N=1,409) had a mean age (SD) of 49.3 (12.4) years, with a mean time since diagnosis (SD) of 6.1 (7.8) and 7.0 (8.0) years, respectively. Of pts with axSpA, 130 (15.3%) had a history of uveitis; 21 (1.5%) pts with PsA had a history of uveitis. The majority of pts with axSpA were human leukocyte antigen (HLA)-B27 positive (717/848 [84.6%]). In pts with axSpA across the pooled phase 2b/3 axSpA trial data, BKZ exposure was 2,514 PY. Uveitis occurred in 31/848 (3.7%; EAIR [95% confidence interval; CI]: 1.3/100 PY [0.9, 1.8]) pts overall and in 18/130 (13.8%; 4.8/100 PY [2.8, 7.6]) pts with history of uveitis. In pts without a history of uveitis, 13/718 (1.8%; 0.6/100 PY [0.3, 1.1]) pts had uveitis events (Figure). All events were mild/moderate, 1 led to treatment discontinuation. Incidence of uveitis in pts with PsA was low across the pooled phase 2b/3 PsA trial data (total BKZ exposure: 3,656 PY); uveitis occurred in 3 (0.2%; 0.1/100 PY [0.0, 0.2]) pts overall; 1 had a history of uveitis. No uveitis events led to treatment discontinuation. Figure. Incidence of uveitis (EAIR/100 PY [95% CI]) in patients with axSpA stratified by history of uveitis Conclusion Across 2,514 PY in pts with axSpA and 3,656 PY in pts with PsA, the long-term incidence of uveitis in pts treated with BKZ remained low. Previously submitted to: ACR 2024.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.013
metaresearch head score (Gemma)0.011
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.013
Threshold uncertainty score0.070

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0130.011
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.003
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0000.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.290
Teacher spread0.276 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueThe Journal of RheumatologySame topicOcular Diseases and Behçet’s SyndromeFrench-language works237,207